FTC Approves Final Order Requiring Elanco, Bayer to Sell Assets

The Federal Trade Commission has approved a final order requiring animal health products suppliers Elanco Animal Health’s and Bayer Animal Health to divest assets in three product markets as a condition of the proposed $7.6 billion acquisition.

• The final order requires Elanco to divest its canine otitis externa treatment, Osurnia, to Dechra; its fast-acting oral treatment that kills adult fleas on dogs, Capstar, to PetIQ, LLC; and its brand name cattle pour-on insecticide, StandGuard, to Neogen
• Each divestiture requires Elanco to transfer all intellectual property and other related assets to the respective buyer

To view the source of this information ...